Company’s 36-month beta value is 1.06.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 7 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for BBIO is 147.70M, and currently, short sellers hold a 11.59% ratio of that floaft. The average trading volume of BBIO on December 26, 2024 was 2.06M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BBIO) stock’s latest price update
The stock of BridgeBio Pharma Inc (NASDAQ: BBIO) has increased by 2.74 when compared to last closing price of 27.77. Despite this, the company has experienced a -0.04% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-13 that PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for acoramidis for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered near-complete (≥90%) transthyretin (TTR) stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. In the Phase 3 study ATTRibute-CM, acoramidis showed clear benefits on cardiovascular outcomes.
BBIO’s Market Performance
BridgeBio Pharma Inc (BBIO) has experienced a -0.04% fall in stock performance for the past week, with a 18.74% rise in the past month, and a 13.46% rise in the past quarter. The volatility ratio for the week is 5.42%, and the volatility levels for the past 30 days are at 5.50% for BBIO. The simple moving average for the last 20 days is 3.89% for BBIO stock, with a simple moving average of 7.24% for the last 200 days.
Analysts’ Opinion of BBIO
Piper Sandler gave a rating of “Overweight” to BBIO, setting the target price at $46 in the report published on September 04th of the current year.
BBIO Trading at 10.43% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.63% of loss for the given period.
Volatility was left at 5.50%, however, over the last 30 days, the volatility rate increased by 5.42%, as shares surge +4.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.67% upper at present.
During the last 5 trading sessions, BBIO rose by +2.55%, which changed the moving average for the period of 200-days by -1.42% in comparison to the 20-day moving average, which settled at $27.50. In addition, BridgeBio Pharma Inc saw -31.11% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from Kumar Neil, who sale 27,389 shares at the price of $22.41 back on Nov 19 ’24. After this action, Kumar Neil now owns 4,897,443 shares of BridgeBio Pharma Inc, valued at $613,826 using the latest closing price.
STEPHENSON BRIAN C, the Secretary, Treasurer & CFO of BridgeBio Pharma Inc, sale 4,156 shares at $22.41 during a trade that took place back on Nov 19 ’24, which means that STEPHENSON BRIAN C is holding 93,758 shares at $93,137 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -2.48 for the present operating margin
- 0.98 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -2.02. The total capital return value is set at -1.03.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated 3.51 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at -1.4. The interest coverage ratio of the stock is -6.03.
Currently, EBITDA for the company is -565.47 million with net debt to EBITDA at -4.18. When we switch over and look at the enterprise to sales, we see a ratio of 31.48. The receivables turnover for the company is 455.58for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.19.
Conclusion
In a nutshell, BridgeBio Pharma Inc (BBIO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
